Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Cancer Immunology, Immunotherapy : CII|August 22, 2023
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infectionsC Schmitt, E P Hoefsmit, T Fangmeier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialA M Menzies, M T Ashworth, S Swann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic MelanomaA Arance, M-A Berciano-Guerrero, J Guo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanomaA M Menzies, S N Lo, R P M Saw, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patientsC Robert, G V Long, J Larkin, et al.
Clinical and Experimental Immunology|August 1, 2020
Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitisS C Sasson, J J Zaunders, K Nahar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabA M Menzies, D B Johnson, S Ramanujam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanomaM T Tetzlaff, C Adhikari, S Lo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaY J L Jansen, E A Rozeman, R Mason, et al.
Pageof 6